ncRNA basic information
ncRNA ID:
ENSG00000177640
ncRNA Database:
Ensembl
ncRNA Name:
CASC2
ncRNA Type:
lncRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qPCR
ncRNA Target Gene:
mTOR
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00853 (APRD00557)
Drug Name:
Temozolomide
Drug Method:
Glioma and the adjacent non-cancerous tissues from 32 patients were collected. The expressions of CASC2 and miR-193a-5p were determined by PCR, and their correlation was analyzed. The correlation between CASC2 expression and the clinical characteristics of patients was also studied. Glioma cells were treated with TMZ to acquire the TMZ-resistant cell lines in which the expressions of CASC2, miR-193a-5p, and mTOR were measured. The regulatory roles of CASC2, miR-193a-5p, and mTOR were defined through the loss of function and luciferase reporter assays. Autophagy was inhibited by autophagy inhibitor 3-MA, CASC2 and mTOR overexpression, or miR-193a-5p inhibitor, and the effect of which on cell viability, apoptosis, and migration of TMZ-resistant glioma cells was evaluated.
Drug Response:
sensitive
Cancer basic information
Cancer:
glioma
Tissue/Cell:
cell line ( U257,U87, U257TR, U87TR)
Other information
Title:
Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Journal:
Biomed Pharmacother
Published:
2018
PubMed ID:
29136760